Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emcure PharmaceuticalsNSE:EMCURE +0.49%41 3-Year ROIIC % is 12.13 as of Mar. 2026, which is 4565% above its 10-year median of 0.26. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 946 Drug Manufacturers companies, Emcure Pharmaceuticals ranks better than 63.11% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Emcure Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 12.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Emcure Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
NSE:EMCURE's 3-Year ROIIC % is ranked better than 63.11% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.61
vs NSE:EMCURE: 12.13
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Emcure Pharmaceuticals 3-Year ROIIC % Related Terms
Emcure Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Emcure Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Emcure Pharmaceuticals (NSE:EMCURE) has a 3-Year ROIIC % of 12.13 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Emcure Pharmaceuticals and its competitors. This is 4565% above median its historical median of 0.26. According to the industry distribution chart, Emcure Pharmaceuticals ranks #349 out of 946 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Emcure Pharmaceuticals' 3-Year ROIIC % too high?
Emcure Pharmaceuticals' current 3-Year ROIIC % of 12.13 is 4565% above median its 10-year median of 0.26. The Drug Manufacturers industry median 3-Year ROIIC % is 3.61. Emcure Pharmaceuticals' value of 12.13 is 236% above this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #349 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #349 out of 946 companies for 3-Year ROIIC %. This puts Emcure Pharmaceuticals in the upper half of its industry. The industry median 3-Year ROIIC % is 3.61. Emcure Pharmaceuticals' value of 12.13 is 236% above this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 3.61, Emcure Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.61, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current 3-Year ROIIC % of 12.13 is 236% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current 3-Year ROIIC % is 12.13, which is 4565% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current 3-Year ROIIC % of 12.13. The current 3-Year ROIIC % is 12.13, which is 4565% above median its 10-year median of 0.26 and 236% above the Drug Manufacturers industry median of 3.61. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current 3-Year ROIIC % is 12.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
